Atlas Trials

Retreatment With Epidermal Growth Factor Receptor(EGFR) Tyrosine Kinase Inhibitor in EGFR Mutation Positive Patients

Clinical trial NCT03382795 · UNKNOWN

Trial details

NCT number
NCT03382795
Sponsor
Korea University Guro Hospital
Status
UNKNOWN
Phase
Phase 2
Study type
INTERVENTIONAL
EGFR Positive Non-small Cell Lung Cancer
Start date
2018-01-03
Primary completion
2023-03-31
Enrollment
63

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.